#BIO22: Com­ing to­geth­er at a crit­i­cal time, End­points News looks at the key met­rics on bio­phar­ma in a tur­bu­lent time

Back at the be­gin­ning of the year dur­ing JP Mor­gan, I came up with my usu­al set of pro­jec­tions for the year ahead and def­i­nite­ly got one thing wrong. The biotech IPO mar­ket, I said in Jan­u­ary, would re­main weak, cre­at­ing a ma­jor fund­ing is­sue for biotech.

Here’s me in a dis­cus­sion with Catal­ent ex­ec­u­tive chair­man John Chimin­s­ki:

What you’ve had for sev­er­al years is a boom­ing biotech field, lots of mon­ey pum­mel­ing in­to the busi­ness and push­ing it up. So when you re­move IPOs as an al­ter­na­tive source of mon­ey for a lot of com­pa­nies, it will make deal-mak­ing more (at­trac­tive).

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.